http://www.fpnotebook.com/
Psychoactive Bath Salts
Aka: Psychoactive Bath Salts, Bath Salts Intoxication, PABS, Methylenedioxypyrovalerone, MDPV, Ivory Wave, Vanilla Sky, Energy-1, Plant Fertilizer, Legal Cocaine
- Mechanism
- Synthetic designer drug (Illicit Drug)
- Methylenedioxypyrovalerone (MDPV) is active ingredient in Psychoactive Bath Salts
- MDPV is related to pyrovalerone and alpha-pyrrolidinophenones
- Inhibit Norepinephrine and Dopamine reuptake
- Act as CNS stimulants
- Appear to have worst characteristics of LSD, PCP, MDMA, Cocaine and Methamphetamine
- Addictive potential
- Tolerance, withdrawal and craving with long term use
- Marketing claims
- Stimulant
- Alertness enhancer
- Aphrodesiac
- Pharmacokinetics
- Lowest effective dose: 3-5 mg intranasally, per-rectum or intravenous
- Average dose 5-20 mg
- Peak rush effect at 1.5 hours after oral ingestion
- Duration of 3-4 hours with "harsh crash"
- Entire course from intake may last 8 hours
- Signs
- Sympathetic stimulation
- Tachycardia
- Hypertension
- Hyperthermia
- Seizures
- Arrhythmias
- Vasoconstriction
- Mydriasis
- Altered Level of Consciousness
- Anxiety
- Severe Panic Attack
- Agitation
- Paranoia
- Hallucinations
- Psychosis
- Violent Behavior or aggressive behavior
- Self-destructive behavior or self-mutilation
- Insomnia
- Anorexia
- Depressed mood
- Labs
- No current lab tests detect Psychoactive Bath Salts
- Precautions
- Polysubstance overdose with bath salts may occur
- Coingestion occurs in 94% of cases (often with Cocaine)
- May confuse the presentation
- Management
- ICU monitoring
- Intravenous fluids
- Physical Restraints may be needed
- Benzodiazepines IV
- Sedation
- Seizure managament
- Supportive care
- Complications
- Overdose is a significant risk with packages containing as much as 500 mg
- Cerebrovascular Accident or cerebral edema
- Respiratory distress
- Rhabdomylolysis
- Arrhythmias, Myocardial Infarction or cardiovascular collapse
- Deaths have been reported
- Resources
- U.S. DEA Site
- http://www.deadiversion.usdoj.gov/drugs_concern/
- References
- Ross (2011) N Engl J Med 365(10): 967-8